Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA (S.A.M.C., Y.D., S.P.M., M.H., R.H.F., S.D.).
CV imaging program, Cardiovascular Division and Department of Radiology, Brigham and Women's Hospital, Boston, MA (S.A.M.C., Y.D., G.O., S.D.).
Circ Cardiovasc Imaging. 2022 Nov;15(11):e014645. doi: 10.1161/CIRCIMAGING.122.014645. Epub 2022 Nov 15.
Echocardiographic deformation-based ratios and novel multi-parametric scores have been suggested to discriminate transthyretin cardiac amyloidosis (ATTR-CM) from other causes of increased left ventricular wall thickness among patients referred for ATTR-CM evaluation. Their relative predictive accuracy has not been well studied. We sought to (1) identify echocardiographic parameters predictive of ATTR-CM and (2) compare the diagnostic accuracy of these parameters in patients with suspected ATTR-CM referred for technetium-99m-pyrophosphate scintigraphy.
Echocardiograms from 598 patients referred to 3 major amyloidosis centers for technetium-99m-pyrophosphate to detect ATTR-CM were analyzed, including longitudinal strain (LS) analysis. Deformation ratios (septal apex to base ratio, relative apical sparing, ejection fraction to global LS), a multi-center European increased wall thickness score, and Mayo Clinic derived ATTR score (transthyretin cardiac amyloidosis score) were calculated. A logistic regression model was used to identify the parameters that best associated with a diagnosis of ATTR-CM. Comparison of the diagnostic capacity of the parameters was performed by receiver operating characteristic curves and the area under the curve (AUC).
Over half of the subjects (54.2%) were diagnosed with ATTR-CM (78% were men, median age of 76 years). Age, inferolateral wall thickness, and basal LS were the strongest predictors of ATTR-CM, AUC of 0.87 (95% CI: 0.83, 0.90), superior to the increased wall thickness score AUC of 0.78 (95% CI: 0.73, 0.83; =0.004). An inferolateral wall thickness of ≥14 mm (AUC: 0.73) was as accurate as the published cut-offs for transthyretin cardiac amyloidosis score and septal apex to base (AUC: 0.72 and 0.69, =0.8 and =0.1, respectively), and was superior to ejection fraction to global LS and relative apical sparing (AUC: 0.64 and 0.53, <0.001, respectively). A cut-off of ≥-8% for average basal LS (AUC: 0.76, CI: 0.72-0.79) had a similar area under the curve to transthyretin cardiac amyloidosis score (TCAS) (=0.2); outperforming the other indices (<0.01).
Inferolateral wall thickness and average basal LS performed as well as or better than more complex echo ratios and multiparametric scores to predict ATTR-CM.
超声心动图变形比值和新型多参数评分已被建议用于区分转甲状腺素蛋白心脏淀粉样变性(ATTR-CM)与其他导致左心室壁增厚的原因,这些原因是患者接受ATTR-CM 评估的原因。它们的相对预测准确性尚未得到很好的研究。我们试图(1)确定预测ATTR-CM 的超声心动图参数,(2)比较这些参数在疑似ATTR-CM 患者中的诊断准确性,这些患者被转诊进行锝-99m-焦磷酸盐闪烁显像术检查。
分析了 598 名因疑似 ATTR-CM 而被转诊至 3 家主要淀粉样变性中心进行锝-99m-焦磷酸盐闪烁显像术检查的患者的超声心动图,包括纵向应变(LS)分析。计算了变形比(隔尖到基底部比,相对尖部保留,射血分数与整体 LS 比),多中心欧洲增加壁厚度评分和 Mayo 诊所衍生的ATTR 评分(转甲状腺素蛋白心脏淀粉样变性评分)。使用逻辑回归模型确定与 ATTR-CM 诊断最相关的参数。通过接收者操作特征曲线和曲线下面积(AUC)比较参数的诊断能力。
超过一半的患者(54.2%)被诊断为 ATTR-CM(78%为男性,中位年龄为 76 岁)。年龄,下外侧壁厚度和基底 LS 是 ATTR-CM 的最强预测因子,AUC 为 0.87(95%CI:0.83,0.90),优于增加壁厚度评分 AUC 的 0.78(95%CI:0.73,0.83;=0.004)。下外侧壁厚度≥14mm(AUC:0.73)与转甲状腺素蛋白心脏淀粉样变性评分和隔尖到基底部的发表截距一样准确(AUC:0.72 和 0.69,=0.8 和=0.1,分别),优于射血分数与整体 LS 和相对尖部保留(AUC:0.64 和 0.53,<0.001,分别)。平均基底 LS 的≥-8%的截止值(AUC:0.76,CI:0.72-0.79)与转甲状腺素蛋白心脏淀粉样变性评分(TCAS)的 AUC 相似(=0.2);优于其他指标(<0.01)。
下外侧壁厚度和基底 LS 与更复杂的超声心动图比值和多参数评分一样,可以预测ATTR-CM。